Market Cap 3.87B
Revenue (ttm) 806.78M
Net Income (ttm) -363.30M
EPS (ttm) N/A
PE Ratio 6.84
Forward PE 6.39
Profit Margin -45.03%
Debt to Equity Ratio -12.83
Volume 623,000
Avg Vol 1,273,868
Day's Range N/A - N/A
Shares Out 79.26M
Stochastic %K 35%
Beta 0.51
Analysts Strong Sell
Price Target $62.94

Company Profile

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spina...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 222 7000
Fax: 908 222 7231
Address:
500 Warren Corporate Center Drive, Warren, United States
Quantumup
Quantumup Jun. 26 at 5:17 PM
B.Riley🏁 $CAPR Buy-$21 and said, "We expect post-approval high growth, as Deramiocel expansion could see >$1B in peak revenue." - '1002 is expected to see favorable comm env w/ 100-200 pt base=$25-$50M in top-line rev w/in 1st Q of launch. $PTCT $SRPT $EWTX B.Riley said in its initiation report:
0 · Reply
Quantumup
Quantumup Jun. 25 at 6:09 PM
Guggenheim reiterated $LRMR Buy-$26 and said, "Yesterday, we hosted $LRMR mgmt (Carole Ben-Maimon, CEO; Michael Celano, CFO; and Tom Hamilton, Board Member) for an in-person NDR in NY." $BIIB $PTCT Guggenheim additionally said, "Investor focus was on the FDA requirements for nomlabofusp BLA filing and on the company's expectations for the OLE readout in September. Guggenheim provided its Key Takeaways and additional commentary (in image below)⤵️
0 · Reply
Quantumup
Quantumup Jun. 23 at 5:41 PM
Citi reiterated $LRMR Buy-$14. $PTCT $BIIB Citi said in its note, "Larimar announced that the FDA recommended the safety database for nomla include at least 30 patients with continuous exposure for six months, including a subset of at least 10 patients for one year, with the large majority receiving the 50mg dose. This builds upon prior disclosures on FDA alignment to utilize skin frataxin concentrations as a surrogate endpoint for accelerated approval, with patient lipid profiles and gene expression changes serving as supportive data (here). With full FDA alignment in hand, Larimar has a clear path to BLA submission, which is now guided for 2Q26 (vs. YE25) to allow for additional time to collect 1 year of safety follow-up for patients on 50mg nomla. Despite the ~2-quarter delay in to BLA submission, management shared the timing for a potential launch remains unchanged and guided to 1Q27 for the first time. We are buyers on today's weakness. Buy/High Risk, TP $14/shr."
0 · Reply
Quantumup
Quantumup Jun. 23 at 1:07 PM
Leerink reiterated $LRMR Outperform-$25. $BIIB $PTCT Leerink said in its note:
0 · Reply
ils85
ils85 Jun. 23 at 12:21 PM
0 · Reply
DonCorleone77
DonCorleone77 Jun. 23 at 11:06 AM
$PTCT PTC Therapeutics announces Sephience granted marketing authorization by EC PTC Therapeutics announced that Sephience was granted marketing authorization by the European Commission, EC, for the treatment of children and adults living with phenylketonuria, PKU. The authorization includes a broad label inclusive of all ages and disease severities. "The European approval of Sephience is a great step in our efforts to bring this safe and highly effective therapy to children and adults affected by PKU worldwide," said Matthew Klein, M.D., Chief Executive Officer of PTC Therapeutics. "The broad label supports that potential for Sephience to address all key PKU patient segments and become the new standard of care."
0 · Reply
ils85
ils85 Jun. 23 at 10:42 AM
$PCSA $PCSA 🚨 All lining up: 🔹 Armistice Capital just reaffirmed their 9.99% stake (578,605 shares) in today’s 13G. 🔹 $7M offering closed—cash in hand, priced smart. 🔹 Licensing deal signed with Intact Therapeutics for their gastroparesis candidate—big market, major unmet need. 🧠 Armistice runs a $6B+ biotech-heavy book ($PTCT, $TVTX, $SUPN). They don’t guess—they position. 💡 PCSA’s now funded, partnered, and backed by smart money. The float is tiny. Any spark sends this vertical. 🚀 Catalyst season is just beginning. Don’t sleep. #biotech #undervalued #catalysts #smartmoney #lowfloat
1 · Reply
dgbio
dgbio Jun. 20 at 9:43 PM
$PTCT Truist initiates with a 'Buy' and $80 target on expected launches of sepiapterin and vatiquinone.
0 · Reply
Quantumup
Quantumup Jun. 10 at 6:16 PM
Canaccord Genuity reiterated $ACAD Buy-$32 and said, "Recall our fundamentals-based BUY thesis on $ACAD has been based on three key factors: ABBV $AXSM $PTCT $RARE $SLNO AARD RYTM Canaccord Genuity went on to say:
0 · Reply
Estimize
Estimize Jun. 2 at 11:00 AM
Wall St is expecting -1.04 EPS for $PTCT Q2 [Reporting 07/31 AMC] http://www.estimize.com/intro/ptct?chart=historical&metric_name=eps&utm_c
0 · Reply
Latest News on PTCT
PTC Therapeutics, Inc. (PTCT) Q1 2025 Earnings Call Transcript

May 6, 2025, 11:19 PM EDT - 7 weeks ago

PTC Therapeutics, Inc. (PTCT) Q1 2025 Earnings Call Transcript


PTC518 PIVOT-HD Study Achieves Primary Endpoint

May 5, 2025, 7:00 AM EDT - 7 weeks ago

PTC518 PIVOT-HD Study Achieves Primary Endpoint


PTC Therapeutics to Participate at Upcoming Investor Conferences

Apr 24, 2025, 8:00 AM EDT - 2 months ago

PTC Therapeutics to Participate at Upcoming Investor Conferences


Vaccine stocks fall following FDA resignation

Mar 31, 2025, 6:21 PM EDT - 3 months ago

Vaccine stocks fall following FDA resignation

BNTX MRNA NVAX PFE PCVX XBI


PTC Therapeutics: Upside In Rare Disease Innovation

Mar 9, 2025, 9:47 AM EDT - 3 months ago

PTC Therapeutics: Upside In Rare Disease Innovation


PTC Therapeutics, Inc. (PTCT) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 9:41 PM EST - 4 months ago

PTC Therapeutics, Inc. (PTCT) Q4 2024 Earnings Call Transcript


PTC Therapeutics to Participate in Upcoming Investor Conferences

Feb 20, 2025, 8:00 AM EST - 4 months ago

PTC Therapeutics to Participate in Upcoming Investor Conferences


Quantumup
Quantumup Jun. 26 at 5:17 PM
B.Riley🏁 $CAPR Buy-$21 and said, "We expect post-approval high growth, as Deramiocel expansion could see >$1B in peak revenue." - '1002 is expected to see favorable comm env w/ 100-200 pt base=$25-$50M in top-line rev w/in 1st Q of launch. $PTCT $SRPT $EWTX B.Riley said in its initiation report:
0 · Reply
Quantumup
Quantumup Jun. 25 at 6:09 PM
Guggenheim reiterated $LRMR Buy-$26 and said, "Yesterday, we hosted $LRMR mgmt (Carole Ben-Maimon, CEO; Michael Celano, CFO; and Tom Hamilton, Board Member) for an in-person NDR in NY." $BIIB $PTCT Guggenheim additionally said, "Investor focus was on the FDA requirements for nomlabofusp BLA filing and on the company's expectations for the OLE readout in September. Guggenheim provided its Key Takeaways and additional commentary (in image below)⤵️
0 · Reply
Quantumup
Quantumup Jun. 23 at 5:41 PM
Citi reiterated $LRMR Buy-$14. $PTCT $BIIB Citi said in its note, "Larimar announced that the FDA recommended the safety database for nomla include at least 30 patients with continuous exposure for six months, including a subset of at least 10 patients for one year, with the large majority receiving the 50mg dose. This builds upon prior disclosures on FDA alignment to utilize skin frataxin concentrations as a surrogate endpoint for accelerated approval, with patient lipid profiles and gene expression changes serving as supportive data (here). With full FDA alignment in hand, Larimar has a clear path to BLA submission, which is now guided for 2Q26 (vs. YE25) to allow for additional time to collect 1 year of safety follow-up for patients on 50mg nomla. Despite the ~2-quarter delay in to BLA submission, management shared the timing for a potential launch remains unchanged and guided to 1Q27 for the first time. We are buyers on today's weakness. Buy/High Risk, TP $14/shr."
0 · Reply
Quantumup
Quantumup Jun. 23 at 1:07 PM
Leerink reiterated $LRMR Outperform-$25. $BIIB $PTCT Leerink said in its note:
0 · Reply
ils85
ils85 Jun. 23 at 12:21 PM
0 · Reply
DonCorleone77
DonCorleone77 Jun. 23 at 11:06 AM
$PTCT PTC Therapeutics announces Sephience granted marketing authorization by EC PTC Therapeutics announced that Sephience was granted marketing authorization by the European Commission, EC, for the treatment of children and adults living with phenylketonuria, PKU. The authorization includes a broad label inclusive of all ages and disease severities. "The European approval of Sephience is a great step in our efforts to bring this safe and highly effective therapy to children and adults affected by PKU worldwide," said Matthew Klein, M.D., Chief Executive Officer of PTC Therapeutics. "The broad label supports that potential for Sephience to address all key PKU patient segments and become the new standard of care."
0 · Reply
ils85
ils85 Jun. 23 at 10:42 AM
$PCSA $PCSA 🚨 All lining up: 🔹 Armistice Capital just reaffirmed their 9.99% stake (578,605 shares) in today’s 13G. 🔹 $7M offering closed—cash in hand, priced smart. 🔹 Licensing deal signed with Intact Therapeutics for their gastroparesis candidate—big market, major unmet need. 🧠 Armistice runs a $6B+ biotech-heavy book ($PTCT, $TVTX, $SUPN). They don’t guess—they position. 💡 PCSA’s now funded, partnered, and backed by smart money. The float is tiny. Any spark sends this vertical. 🚀 Catalyst season is just beginning. Don’t sleep. #biotech #undervalued #catalysts #smartmoney #lowfloat
1 · Reply
dgbio
dgbio Jun. 20 at 9:43 PM
$PTCT Truist initiates with a 'Buy' and $80 target on expected launches of sepiapterin and vatiquinone.
0 · Reply
Quantumup
Quantumup Jun. 10 at 6:16 PM
Canaccord Genuity reiterated $ACAD Buy-$32 and said, "Recall our fundamentals-based BUY thesis on $ACAD has been based on three key factors: ABBV $AXSM $PTCT $RARE $SLNO AARD RYTM Canaccord Genuity went on to say:
0 · Reply
Estimize
Estimize Jun. 2 at 11:00 AM
Wall St is expecting -1.04 EPS for $PTCT Q2 [Reporting 07/31 AMC] http://www.estimize.com/intro/ptct?chart=historical&metric_name=eps&utm_c
0 · Reply
JarvisFlow
JarvisFlow May. 27 at 1:00 PM
Wells Fargo updates rating for PTC Therapeutics ( $PTCT ) to Overweight, target set at 68 → 74.
0 · Reply
BioGLovesMe
BioGLovesMe May. 9 at 4:53 PM
$PTCT This could easily give up all of the recent gains if CHMP adopts the negative Translarna opinion. Will be a close to $200M revenue hit.
1 · Reply
Quantumup
Quantumup May. 8 at 9:19 PM
BofA⬆️ $PTCT to Buy-$68 was Neutral-$55, said "We raise our rating for $PTCT shares to Buy with new $68 PO as we update our model estimates for the PKU (rare metabolic disease) program now estimating $788MN in peak risk-adj. sales (30% of our NPV). $LRMR $BIIB BofA added: "We highlight recent KOL checks in PKU indicate sepiapterin will likely be approved given the high unmet treatment need. While usage expectations vary, we note general consensus assumes initial usage in SoC non responders, which we note is the majority of the PKU population (~70%). We will continue to poll our KOLs ahead of the July 29th PDUFA to understand potential uptake dynamics as well as expectations for early payor coverage dynamics. We also highlight the company's strong balance sheet (net cash: ~ $1.7bn) and current commercial sales provides a floor to valuation, contributing $31/sh to our PO."
0 · Reply
KhamPong
KhamPong May. 8 at 10:33 AM
0 · Reply
JarvisFlow
JarvisFlow May. 7 at 5:33 PM
RBC Capital has updated their rating for PTC Therapeutics ( $PTCT ) to Outperform with a price target of 58.
0 · Reply
RichMitch
RichMitch May. 7 at 3:16 PM
$PTCT .... 💥 💰 Gotta do the opposite 💪😉
0 · Reply
JarvisFlow
JarvisFlow May. 7 at 12:30 PM
JP Morgan has updated their rating for PTC Therapeutics ( $PTCT ) to Overweight with a price target of 67.
0 · Reply
JarvisFlow
JarvisFlow May. 7 at 11:30 AM
Citigroup updates rating for PTC Therapeutics ( $PTCT ) to Neutral, target set at 50 → 40.
0 · Reply
PenkeTrading
PenkeTrading May. 7 at 1:19 AM
I found you an Oversold RSI (Relative Strength Index) on the daily chart of PTC Therapeutics Inc. Is that bullish or bearish? $PTCT #RsiOversold #NASDAQ
0 · Reply
Armonica423
Armonica423 May. 6 at 1:54 PM
$PTCT CYDY
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 6 at 12:08 AM
Attached is an expanded schedule of market caps as multiples of cumulative 10-year analyst revenue estimates compared to the like multiples paid in recent peer M&A transactions. $APLS $FOLD $SRPT $NBIX & $PTCT are right in the middle. NBIX reported strong Q1 25 sales, reaffirmed the year & traded ~10% higher after hours. Even a multiple of 0.22X for NBIX appears competitive v. the peer group. This is not investment advice.
1 · Reply
StockHunter75
StockHunter75 May. 5 at 9:20 PM
$PTCT Added
0 · Reply